Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity
/in Dendritic Cells, Hyperthermia, International Publications, Prostate CancerA combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model
/in Breast Cancer, Dendritic Cells, International PublicationsTherapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours
/in Cervical Cancer, Dendritic Cells, International PublicationsIntratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma
/in Dendritic Cells, Hyperthermia, International Publications, Malignant MelanomaImmunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells
/in Dendritic Cells, International Publications, NSCLCDC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors
/in Dendritic Cells, Hypernephroma, International PublicationsTargeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
/in Breast Cancer, Dendritic Cells, International PublicationsVaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers
/in Breast Cancer, Dendritic Cells, International PublicationsGeneration of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission
/in Acute Leukemia, Dendritic Cells, International Publications, Malignant Lymphoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer